Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754727 | 0.84 | DYRK1A (0.65) | DYRK1AKCNH2CYP2D6CYP2C9GPR142 | |
| SCHEMBL12368117 | 0.81 | DYRK1A (0.45) | DYRK1AKCNH2CYP2D6CYP2C9GPR142 | |
| SCHEMBL15057049 | 0.81 | DYRK1A (0.48) | DYRK1AKCNH2CLK2HASPINSCN10A | |
| SCHEMBL15057624 | 0.81 | DYRK1A (0.48) | DYRK1AKCNH2CLK2HASPINSCN10A | |
| SCHEMBL31729856 | 0.81 | DYRK1A (0.45) | DYRK1AKCNH2CYP2D6CYP2C9GPR142 | |
| SCHEMBL30600082 | 0.80 | DYRK1A (0.55) | DYRK1AKCNH2CLK2HASPINSCN10A | |
| SCHEMBL14072356 | 0.80 | DYRK1A (0.69) | DYRK1ACYP2D6CYP2C9WNT3A | |
| SCHEMBL3270228 | 0.80 | DYRK1A (0.50) | DYRK1AKCNH2CLK2HASPINSCN10A | |
| SCHEMBL12330967 | 0.79 | DYRK1A (0.51) | DYRK1AKCNH2CLK2HASPINSCN10A | |
| SCHEMBL24333225 | 0.78 | DYRK1A (1.00) | DYRK1ACLK2HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| CN-107074805-B | GLS1 inhibitors for the treatment of disease | 德州大学系统董事会 | 2021-02-26 | — | — | CN | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-10766892-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-08 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| CN-107074805-A | GLS1 inhibitor for treating disease | 德州大学系统董事会 | 2017-08-18 | — | — | CN | disclosed |
| EP-3164394-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | Board of Regents, The University of Texas System (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-10766892-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-11370786-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLB1 | DYRK1A 3405/4885KCNH2 1445/4885CYP2D6 2141/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | DYRK1A 4330/4885KCNH2 2074/4885CYP2D6 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.